Willis Towers Watson

WTW · NASDAQ

$325.01−$7.17 (−2.16%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $332.18

WTW analyst rating

BuyConsensus of 15 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy10
Hold5
Underperform0
Sell0

12-month price target · 22 analysts

Average $379.77 (+16.8% upside)

Low: $313.10
Now: $325.01
High: $477.75

Upgrades and downgrades

The latest rating actions, newest first

WTW analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 12, 2026	Maintains	Overweight	$378.00 → $364.00	61%
Mizuho	Oct 7, 2026	Maintains	Outperform	$380.00 → $349.00	63%
Barclays	Oct 7, 2026	Maintains	Equal-Weight	$303.00 → $332.00	62%
Morgan Stanley	Oct 6, 2026	Maintains	Equal-Weight	$350.00 → $310.00	84%
UBS	Oct 6, 2026	Maintains	Buy	$405.00 → $398.00	70%
Mizuho	Sep 16, 2026	Maintains	Outperform	$406.00 → $380.00	63%
TD Cowen	Aug 20, 2026	Maintains	Buy	$391.00 → $455.00	54%
Morgan Stanley	Aug 19, 2026	Maintains	Equal-Weight	$315.00 → $350.00	84%
Keefe, Bruyette & Woods	Aug 4, 2026	Maintains	Outperform	$381.00 → $394.00	70%
UBS	Aug 3, 2026	Maintains	Buy	$382.00 → $405.00	70%

The case for and against

Updated Oct 18, 2026

Bull case

Willis Towers Watson is positioned for durable fundamental improvement as Propel embeds AI, automation, and workflow simplification across the enterprise, supporting an estimated ~$350 million of net run-rate savings by 2028E and helping lift adjusted operating margin from 25.4% LTM 2Q26 to 30.0% by 2028E. That margin expansion is reinforced by 5% organic revenue growth in 2027E and 2028E, with strength expected across both HWC and R&B, plus additional upside from talent investment, higher productivity, and selective M&A such as Newfront. Its 2Q26 results already showed the model working, with revenue of $2.47 billion, adjusted EPS of $3.35, 7% organic growth in R&B, and expanding segment margins, suggesting execution is translating into stronger cash flow and earnings power.

Bear case

Willis Towers Watson is exposed to multiple fundamental headwinds that can weaken both revenue growth and margin performance, including weaker foreign currencies, P&C (re)insurance rate declines, and adverse economic conditions that could dampen demand for consulting, actuarial, and brokerage services. Its business mix leaves it vulnerable to cyclical insurance pricing, with slower commercial lines P&C increases, intensifying auto competition, and rising disintermediation pressure likely to constrain organic growth, especially in brokerage and consulting. The outlook is further pressured by execution and staffing risk, as poorly executed M&A and an inability to retain producers or key staff could impair EPS, while an approximate 10% change in EPS estimates can translate into a similar change in valuation sensitivity.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.